Journal article
Risankizumab in Severe Asthma — A Phase 2a, Placebo-Controlled Trial
Abstract
BACKGROUND: Interleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the treatment of asthma improves disease control and reduces airway inflammation is unclear.
METHODS: We conducted a phase 2a, multicenter, randomized, double-blind, placebo-controlled, 24-week, parallel-group trial to assess the efficacy and safety of risankizumab, an anti-interleukin-23p19 …
Authors
Brightling CE; Nair P; Cousins DJ; Louis R; Singh D
Journal
The New England Journal of Medicine, Vol. 385, No. 18, pp. 1669–1679
Publisher
Massachusetts Medical Society
Publication Date
October 28, 2021
DOI
10.1056/nejmoa2030880
ISSN
0028-4793